Biostock Interview: Chordate’s CEO Anders Weilandt Comments on the Rights Issue

In a new interview with Biostock, Chordate’s CEO Anders Weilandt discusses the rights issue intended to finance ongoing value creation ahead of a potential exit. The proceeds from the issuance will be used, among other things, to establish proof-of-concept in selected markets for the migraine and rhinitis treatment Ozilia.

“We see how the project as a whole has attained a significantly lower risk level due to the highly favorable study results. In the second half of 2023, we observed the fruition of our market efforts. Chordate as an investment should be considered to have transitioned from a technical/scientific development project to a phase of market validation. Investors, of course, have different perspectives, but I assess that this clear shift in risk level should attract investors with experience in life science investments,” says Anders Weilandt to Biostock.

Read the full interview (In Swedish)

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy